These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 7881194)

  • 21. Optimal drug regimens in cancer chemotherapy for single drugs that block progression through the cell cycle.
    Murray JM
    Math Biosci; 1994 Oct; 123(2):183-213. PubMed ID: 7827419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of cell kinetics in the development of drug combinations.
    Valeriote FA
    Pharmacol Ther; 1979; 4(1):1-33. PubMed ID: 461499
    [No Abstract]   [Full Text] [Related]  

  • 23. Some drug-resistant models for cancer chemotherapy. Part 1: Cycle-nonspecific drugs.
    Usher JR; Henderson D
    IMA J Math Appl Med Biol; 1996 Jun; 13(2):99-126. PubMed ID: 8671582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal control of tumor size used to maximize survival time when cells are resistant to chemotherapy.
    Martin RB; Fisher ME; Minchin RF; Teo KL
    Math Biosci; 1992 Jul; 110(2):201-19. PubMed ID: 1498450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A delay differential equation model for tumor growth.
    Villasana M; Radunskaya A
    J Math Biol; 2003 Sep; 47(3):270-94. PubMed ID: 12955460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing drug regimens in cancer chemotherapy: a simulation study using a PK-PD model.
    Barbolosi D; Iliadis A
    Comput Biol Med; 2001 May; 31(3):157-72. PubMed ID: 11173054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance to cytostatic drugs at the cellular level.
    Vendrik CP; Bergers JJ; De Jong WH; Steerenberg PA
    Cancer Chemother Pharmacol; 1992; 29(6):413-29. PubMed ID: 1568284
    [No Abstract]   [Full Text] [Related]  

  • 28. Optimal controls for a model with pharmacokinetics maximizing bone marrow in cancer chemotherapy.
    Ledzewicz U; Schättler H
    Math Biosci; 2007 Apr; 206(2):320-42. PubMed ID: 16197967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regrowth resistance in cancer: why has it been largely ignored?
    Preisler HD; Venugopal P
    Cell Prolif; 1995 Jun; 28(6):347-56. PubMed ID: 7626689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intensive cytotoxic chemotherapy.
    Bagshawe KD
    J R Coll Physicians Lond; 1971 Jan; 5(2):157-66. PubMed ID: 4131399
    [No Abstract]   [Full Text] [Related]  

  • 31. A stochastic model of the acquisition of drug resistance during antineoplastic chemotherapy.
    Abundo M; Rossi C; Benassi M; Gentile FP; Mauro F
    Health Phys; 1989; 57 Suppl 1():349-54. PubMed ID: 2606692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. General applications of optimal control theory in cancer chemotherapy.
    Swan GW
    IMA J Math Appl Med Biol; 1988; 5(4):303-16. PubMed ID: 3241099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular tumor growth and treatment: consequences of polyclonality, competition and dynamic vascular support.
    Jackson TL
    J Math Biol; 2002 Mar; 44(3):201-26. PubMed ID: 12148489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An example of the effects of drug resistance on the optimal schedule for a single drug in cancer chemotherapy.
    Murray JM
    IMA J Math Appl Med Biol; 1995; 12(1):55-69. PubMed ID: 7594878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The dynamics of cell proliferation.
    Moxnes JF; Haux J; Hausken K
    Med Hypotheses; 2004; 62(4):556-63. PubMed ID: 15050107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Kinetics of breast neoplasms].
    Surbone A; Norton L
    Minerva Med; 1994; 85(1-2):7-16. PubMed ID: 8152580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytokinetic aspects of clinical drug resistance.
    Bender RA; Dedrick RL
    Cancer Chemother Rep; 1975; 59(4):805-9. PubMed ID: 1175170
    [No Abstract]   [Full Text] [Related]  

  • 38. A model for metastases formation.
    Markovitch S
    Int J Biomed Comput; 1993 Jan; 32(1):19-33. PubMed ID: 8425750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A critical appraisal of the "human tumor stem-cell assay".
    Selby P; Buick RN; Tannock I
    N Engl J Med; 1983 Jan; 308(3):129-34. PubMed ID: 6336820
    [No Abstract]   [Full Text] [Related]  

  • 40. Quantitative model for multiple levels of drug resistance in clinical tumors.
    Goldie JH; Coldman AJ
    Cancer Treat Rep; 1983 Oct; 67(10):923-31. PubMed ID: 6627236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.